Drug combination demonstrates proof of concept in controlling HCV
from Medscape Medical News
A four-week lead in the dosing of two oral small-molecule drugs was able to reduce the level of hepatitis C virus (HCV) RNA to undetectable levels in a small number of patients before either ribavirin or an interferon/RBV combination was added to the regimen.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063